| Oxidized phospholipids: from molecular properties to disease GO Fruhwirth, A Loidl, A Hermetter Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1772 (7), 718-736, 2007 | 334 | 2007 |
| RhoA and RhoC have distinct roles in migration and invasion by acting through different targets FM Vega, G Fruhwirth, T Ng, AJ Ridley Journal of Cell Biology 193 (4), 655-665, 2011 | 317 | 2011 |
| Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection DA Boardman, C Philippeos, GO Fruhwirth, MAA Ibrahim, RF Hannen, ... American Journal of Transplantation 17 (4), 931-943, 2017 | 302 | 2017 |
| Seeds and oil of the Styrian oil pumpkin: Components and biological activities GO Fruhwirth, A Hermetter European Journal of Lipid Science and Technology 109 (11), 1128-1140, 2007 | 264 | 2007 |
| Regional activation of myosin II in cancer cells drives tumor progression via a secretory cross-talk with the immune microenvironment M Georgouli, C Herraiz, E Crosas-Molist, B Fanshawe, O Maiques, ... Cell 176 (4), 757-774. e23, 2019 | 143 | 2019 |
| 3D super-resolution imaging with blinking quantum dots Y Wang, G Fruhwirth, E Cai, T Ng, PR Selvin Nano letters 13 (11), 5233-5241, 2013 | 133 | 2013 |
| RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers S Irshad, F Flores-Borja, K Lawler, J Monypenny, R Evans, V Male, ... Cancer research 77 (5), 1083-1096, 2017 | 120 | 2017 |
| Production technology and characteristics of Styrian pumpkin seed oil GO Fruhwirth, A Hermetter European journal of lipid science and technology 110 (7), 637-644, 2008 | 104 | 2008 |
| In vivo PET tracking of 89Zr-labeled Vγ9Vδ2 T cells to mouse xenograft breast tumors activated with liposomal alendronate F Man, L Lim, A Volpe, A Gabizon, H Shmeeda, B Draper, ... Molecular Therapy 27 (1), 219-229, 2019 | 100 | 2019 |
| Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines S Edmonds, A Volpe, H Shmeeda, AC Parente-Pereira, R Radia, ... ACS nano 10 (11), 10294-10307, 2016 | 99 | 2016 |
| Fluorescence screening of antioxidant capacity in pumpkin seed oils and other natural oils GO Fruhwirth, T Wenzl, R El‐Toukhy, FS Wagner, A Hermetter European Journal of Lipid Science and Technology 105 (6), 266-274, 2003 | 94 | 2003 |
| Imaging of T-cells and their responses during anti-cancer immunotherapy M Krekorian, GO Fruhwirth, M Srinivas, CG Figdor, S Heskamp, TH Witney, ... Theranostics 9 (25), 7924, 2019 | 83 | 2019 |
| Mediation of apoptosis by oxidized phospholipids GO Fruhwirth, A Hermetter Lipids in Health and Disease, 351-367, 2008 | 80 | 2008 |
| A catalase-peroxidase from a newly isolated thermoalkaliphilic Bacillus sp. with potential for the treatment of textile bleaching effluents M Gudelj, G Fruhwirth, A Paar, F Lottspeich, KH Robra, A Cavaco-Paulo, ... Extremophiles 5, 423-429, 2001 | 80 | 2001 |
| WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion I Rodriguez-Hernandez, O Maiques, L Kohlhammer, G Cantelli, ... Nature communications 11 (1), 5315, 2020 | 72 | 2020 |
| The oxidized phospholipids POVPC and PGPC inhibit growth and induce apoptosis in vascular smooth muscle cells GO Fruhwirth, A Moumtzi, A Loidl, E Ingolic, A Hermetter Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2006 | 72 | 2006 |
| The future of regulatory T cell therapy: promises and challenges of implementing CAR technology YR Mohseni, SL Tung, C Dudreuilh, RI Lechler, GO Fruhwirth, ... Frontiers in immunology 11, 545396, 2020 | 71 | 2020 |
| Kinase-mediated quasi-dimers of EGFR EM Bublil, G Pines, G Patel, G Fruhwirth, T Ng, Y Yarden The FASEB Journal 24 (12), 4744, 2010 | 69 | 2010 |
| Fluorescence lifetime endoscopy using TCSPC for the measurement of FRET in live cells GO Fruhwirth, S Ameer-Beg, R Cook, T Watson, T Ng, F Festy Optics express 18 (11), 11148-11158, 2010 | 67 | 2010 |
| The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients MT Kelleher, G Fruhwirth, G Patel, E Ofo, F Festy, PR Barber, ... Targeted oncology 4, 235-252, 2009 | 63 | 2009 |
Alessia VolpeMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
